tbuckley/cabot-search huggingface dataset:
Cuffite: existe-t-il un traitement endoscopique?
Authors: M Serrero, A Santoni, JC Grimaud, A Desjeux, JM Gonzalez, M Barthet
Journal: Endoscopy (2019)

La coloprotectomie totale avec anastomose iléo-anale est le traitement de référence pour les patients atteints d'une rectocolite hemorragique (RCH) refractaire au traitement médical. L'une des complications lors de la confection d'une anastomose iléo-anale mécanique par technique d'agrafage est de laisser en place une bande de muqueuse rectale pouvant être le siège d'une inflammation persistante appelée cuffite. L'objectif de notre étude était de présenter une approche endoscopique pour le traitement de la cuffite.
THER-16. INTERACTION OF IMMUNE SYSTEM WITH ONCOLYTIC MEASLES VIRUS THERAPY IN AN MV-SENSITIVE IMMUNOCOMPETENT MURINE MODEL OF MEDULLOBLASTOMA
Authors: Sangeet Lal, Sabine Mueller, Nalin Gupta, Corey Raffel
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION: Oncolytic viruses selectively replicate in tumor cells, and may attract immune cells into the microenvironment to stimulate a systemic antitumor response. We have shown efficacy of oncolytic measles virus (MV) against medulloblastoma (MB) in preclinical models. To study the effect of immune system on MV therapy, we have developed the first immunocompetent MV-sensitive murine model of Group 3 MB (CSCG model) and showed that intratumoral MV treatment of tumor-bearing mice significantly prolonged survival. Herein, we study the interaction of MV therapy and tumor immune microenvironment in this model. METHODS: Naive and MV-preimmunized mice were injected with 200,000 CSCG tumor cells in caudate putamen and tumor-bearing mice were treated identically with intratumoral MV injections (n=5 per group). Tumor growth was monitored by bioluminescence imaging and RT-PCR was performed to assess infiltrating CD4+ and CD8+ T cells in MV-treated and untreated control tumors. RESULTS: RT-PCR of untreated tumors shows an average of 43.4 ±1.45-fold and 13.24 ±1.34-fold increase in infiltrating CD8+T cells and CD4+T cells, respectively, compared to normal brain (n=3). Tumors that responded to MV therapy, but recurred had a dramatic decrease in infiltrating CD8+T cells (2.66 ±0.8-fold higher than normal brain). No significant difference in survival was observed between MV-naive and MV-immunized mice (p= 0.773), indicating that anti-measles immunity does not affect MV efficacy, an important point given that almost all patients have been vaccinated with MV. Long-term survivors, both naïve and MV-immune, remained tumor-free for at least 150 days post treatment. These mice (n=3) were re-challenged with a 3-fold higher number of tumor cells than the original injection, but tumor failed to grow for at least 50 days post-injection. CONCLUSION: This finding strongly suggests MV treatment induces anti-tumor immunity. Ongoing studies are being performed to dissect this immune response and to explore the possibility of enhancing it.
LONG-TERM CLINICAL OUTCOMES OF ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) IN GASTRIC EPITHELIAL LESIONS: A SPANISH SINGLE-CENTER COHORT
Authors: Á Cañete Ruiz, J Arribas Anta, T Álvarez-Nava Torrego, C Piedracoba Cadahía, E Romero Romero, DR de la Cruz, M Rodriguez Carrasco, A del Pozo García, J Díaz Tasende, JC Marín Gabriel
Journal: Endoscopy (2019)

To analyze recurrence rates at 5-year follow-up after gastric ESD in a cohort of patients, according to different variables.
Resistin-like Molecule α Provides Vitamin-A-Dependent Antimicrobial Protection in the Skin
Authors: Tamia A. Harris, Sureka Gattu, Daniel C. Propheter, Zheng Kuang, Shai Bel, Kelly A. Ruhn, Andrew L. Chara, Marshall Edwards, Chenlu Zhang, Jay-Hyun Jo, Prithvi Raj, Christos C. Zouboulis, Heidi H. Kong, Julia A. Segre, Lora V. Hooper
Journal: Cell Host & Microbe (2019)
Factors associated with Legionnaires’ disease recurrence in hotel and holiday rental accommodation sites
Authors: Julien Beauté, Sven Sandin, Birgitta de Jong, Lara Payne Hallström, Emmanuel Robesyn, Johan Giesecke, Pär Sparén
Journal: Eurosurveillance (2019)

Background The detection of a cluster of travel-associated Legionnaires’ disease (TALD) cases in any European Union/European Economic Area (EU/EEA) country prompts action at the accommodation, follow-up by health authorities and reporting of measures taken. Some accommodations incur further cases despite presumed implementation of adequate control measures. Aim To identify factors associated with the occurrence of a further TALD case after the implementation of control measures. Methods We conducted a retrospective cohort study of hotel and holiday rental accommodations in the EU/EEA associated with two or more TALD cases with onset dates less than 2 years apart (a ‘cluster’) and notification between 1 June 2011−31 December 2016. We fitted Cox regression models to estimate the association between accommodation characteristics and the occurrence of a further case, defined as any case with onset date after the report on measures taken. Results Of the 357 accommodations in the analysis, 90 (25%) were associated with at least one further case after the report on measures taken (12.4/100 accommodation-years). Accommodations associated with two or more cases before the cluster notification were more likely to be associated with a further case, compared with those not previously associated with any case (adjusted hazard ratio 1.85; 95% confidence interval: 1.14–3.02). Neither the detection of Legionella in the water system nor the type of disinfection were found to be associated with the risk of a further case. Conclusion Accommodation size and previous TALD cases were predictive of further Legionnaires’ disease cases after implementation of control measures.
Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma
Authors: Rebecca A. Luchtel, Michael T. Zimmermann, Guangzhen Hu, Surendra Dasari, Manli Jiang, Naoki Oishi, Hailey K. Jacobs, Yu Zeng, Tanya Hundal, Karen L. Rech, Rhett P. Ketterling, Jeong-Heon Lee, Bruce W. Eckloff, Huihuang Yan, Krutika S. Gaonkar, Shulan Tian, Zhenqing Ye, Marshall E. Kadin, Jagmohan Sidhu, Liuyan Jiang, Jesse Voss, Brian K. Link, Sergei I. Syrbu, Fabio Facchetti, N. Nora Bennani, Susan L. Slager, Tamas Ordog, Jean-Pierre Kocher, James R. Cerhan, Stephen M. Ansell, Andrew L. Feldman
Journal: Blood (2019)
Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand
Authors: Lin Mei, Junran Zhang, Kai He, Jingsong Zhang
Journal: Journal of Hematology & Oncology (2019)

The ataxia telangiectasia and Rad3-related (ATR) checkpoint kinase 1 (CHK1) pathway plays an essential role in suppressing replication stress from DNA damage and oncogene activation. Preclinical studies have shown that cancer cells with defective DNA repair mechanisms or cell cycle checkpoints may be particularly sensitive to ATR inhibitors. Preclinical and clinical data from early-phase trials on three ATR inhibitors (M6620, AZD6738, and BAY1895344), either as monotherapy or in combination, were reviewed. Data from ATR inhibitor-based combinational trials might lead to future expansion of this therapy to homologous recombination repair pathway-proficient cancers and potentially serve as a rescue therapy for patients who have progressed through poly ADP-ribose polymerase inhibitors.
What’s hot that the other lot got
Authors: Mun Jung Jang
Journal: Thorax (2019)

Antibiotic therapy is commonly prescribed to patients with acute exacerbations of asthma, despite scarce evidence and consensus guidelines advocating limited prescribing. Stefan and colleagues ( JAMA Intern Med 2019; E1-E7: doi:10.1001/jamainternmed.2018.5394) investigated the outcomes of antibiotic therapy in hospitalised patients with asthma exacerbations treated with corticosteroids using a retrospective cohort study design. Data were collected from an administrative database in the USA. A propensity score matched analysis was conducted in an attempt to minimise the influence of confounding factors. Additionally, exposure to antibiotics was assessed in the first 2 days of admission to avoid association of subsequent deterioration. The authors included 19 811 adults from 542 acute care hospitals. Patients with a potential indication for antibiotics (eg, COPD, bronchiectasis, pneumonia, etc) were excluded. In the first 2 days of hospital admission, 8788 patients (44.4%) received antibiotics. The median hospital stay in those treated with antibiotics was 4 (3–5) days, compared with 3 (2–4) days in those untreated (p<0.001). Treatment failure rates in the whole cohort was low (5.6%) and did not differ between the groups. Rates of antibiotic-associated diarrhoea were low (1.4% treated vs 1.1% untreated). Suggested mechanisms for the prolongation of the hospital stay include unmeasured confounders (mitigated by trial design) and patients not being discharged until they had completed their course of antibiotics. These results support the current recommendations for limited antibiotic prescribing in non-infective asthma exacerbations and …
Genetic Determinants of Venetoclax Resistance in Lymphoid Malignancies
Authors: Romain Guieze, Vivian M Liu, Daniel Rosebrock, Alexis Jourdain, María Hernández-Sánchez, Aina zurita Martinez, Sun Jing, Kaitlyn J Baranowski, Philip A. Thompson, Heo Jin-Mi, Zacchary Cartun, Ozan Aygun, Giulia Notarangelo, Dimitri Livitz, Shuqiang Li, Matthew S. Davids, Jennifer R. Brown, William G. Wierda, Anthony Letai, Donna S Neuberg, Wade Harper, Steven A. Carr, Federica Piccioni, Christopher J. Ott, Ignaty Leshchiner, Cory Johannessen, John G Doench, Vamsi Mootha, Gad Getz, Catherine J. Wu
Journal: Blood (2018)
Trust admits it was wrong to suspend surgeon and apologises for distress caused
Authors: Clare Dyer
Journal: BMJ (2019)

St George’s University Hospitals NHS Foundation Trust has settled a High Court claim by a leading heart surgeon, admitting that it wrongly excluded her from her job and apologising for the distress the legal proceedings caused her.

Marjan Jahangiri, a professor of cardiac surgery, won an interim High Court injunction last August allowing her back to work pending a full hearing of her claim that the trust’s decision to exclude her was “irrational” and breached her employment contract.1

Now the case has been settled on confidential terms, with the trust also apologising for the decision to stop her working, for …
Nonneoplastic diseases and disorders of the oral mucosa: A contemporary overview
Authors: Anura Ariyawardana, Newell W. Johnson
Journal: Periodontology 2000 (2019)

Abstract Oral mucosal diseases encompass a diverse array of conditions and disorders arising from malignant, potentially malignant, and nonneoplastic processes. Considerable attention has been paid to the former in recent years, much less to the wide range of nonneoplastic disease processes, which constitute a sizeable proportion of the oral disease burden globally. Many nonneoplastic disease processes of the oral mucosa significantly affect the patient's quality of life. Fortunately, timely identification and intervention can reduce the associated morbidity and, sometimes, mortality. As such, it is of utmost importance that dentists are familiar with early identification and management of this wide range of oral mucosal diseases. This volume of Periodontology 2000 provides a comprehensive contemporary review of such diseases and disorders through 15 chapters. We cover all relevant disease categories: developmental anomalies, infections, white and red lesions, vesiculo‐bullous diseases, oral dermatoses, oral ulcerative conditions, dysplastic lesions, and mucosal diseases as manifestations of systemic disease or oral lesions as a part of systemic diseases. Each chapter discusses epidemiology, etiopathogenesis, clinical features, diagnosis, and management. Controversies and many significant gaps in knowledge are exposed, with suggestions for research to address limitations in current understandings. We take a look at the 2017 classification of the periodontal diseases and discuss the importance of close liaison between the specialties of oral medicine and of periodontology in the management of the many oral diseases, apart from the common forms primarily related to oral biofilm, affecting the gingivae and other parts of the periodontium.
Utilization and performance of the Prosigna® breast cancer prognostic gene signature assay at the Medical University of Vienna
Authors: K.A. Tendl, L. Monschein, R. Exner, F. Fitzal, E.S. Bergen, M. Seifert, C.F. Singer, M. Rudas, L. Müllauer, Z.A. Bago-Horvath
Journal: Annals of Oncology (2019)

Background: The Prosigna breast cancer assay provides independent additional prognosic value compared to classic pathohistological and immunohistochemical (IHC) parameters and assists adjuvant therapy decisions. In the present study, we retrospectively evaluated correlation of Prosigna breast cancer assay intrinsic subtype (IST) with immunohistochemical (IHC) IST estimation in a clinical setting. Methods: We included all tumors (150 tumors from 146 women) that were analysed using the Prosigna assay at the Medical University of Vienna between December 2014 and July 2018, and of which detailed IHC status (ER/PR receptor, HER-2 and Ki67) could be accessed. 3 tumors with HER-2 enriched Prosigna IST were excluded from the analysis. For our analysis Ki67 cutoff values alone were used for discriminating Luminal (Lum) A from Lum B IHC IST estimation (Lum B: ≥20%, ≥30% and ≥40% Ki67). In addition the role of the cut off value of KI67 ≥20% and ≥30% in combination with PR receptor expression and grading were evaluated, regarding clinical and genomic correlation for defining subtypes. Statistical analyses were conducted using Cohen's kappa coefficient. Results: In total we analysed 150 tumors from 146 women (median age 55.5 years), of whom 60% were lymph node positive. 79.3% (n = 119) of the tumors were of Prosigna Lum B subtype and 52% (n = 78) IHC Lum B IST, when using a cutoff of ≥ 20% Ki67 for Lum B disease. We found only a fair agreement between Prosigna and IHC IST (kappa 0.326). When using KI67 ≥30% as a cutoff, a slight improvement in agreement (kappa 0.411) was noted. Using a cutoff of ≥ 40 % KI67% to define IHC luminal IST, agreement decreased again (kappa 0.227). Conclusions: Agreement between Prosigna luminal IST and estimation of luminal IST based on IHC over a range of Ki67 cutoff values between 20% to 40% proves to be fair at best. Our study demonstrates, that molecular-genetic tests, such as the Prosigna assay, provide crucial information for adjuvant chemotherapy decision management in cases where Ki67 IST estimation alone is not sufficient for therapy decision. These associations should be addressed by further studies to ensure an exact and cost-effective utilisation of the assay. Legal entity responsible for the study: Department of Pathology, Medical University of Vienna. Disclosure: K.A. Tendl: Travel support: Roche, MSD, Novartis, outside the submitted work. F. Fitzal: Travel support, scientific support: Pfizer, Comesa, Novartis, Roche, AstraZeneca, Pfizer, Myriad, NanoString, Lilly und Bondimed outside the submitted work; Editor for Oncoplastic Surgery part I and II, Springer. L. Müllauer: Research support: NanoString, outside the submitted work. Z.A. Bago-Horvath: Grants: Boehringer Ingelheim; Personal fees: Novartis, Roche; Travel support: Roche, outside the submitted work. All other authors have declared no conflicts of interest.
Abstract 11337: Irradiation Eliminates Residual Induced Pluripotent Stem (iPS) Cells in Cardiomyocytes Derived From Human iPS Cells
Authors: Maki Takeda, Shigeru Miyagawa, Emiko Ito, Akima Harada, Kazumasa Minami, Noriko Mochizuki-Oda, Yoshiki Sawa
Journal: Circulation (2018)

Background: One of major concerns in clinical application of induced pluripotent stem cells (hiPSc) may be how to avoid tumorigenesis after implantation. It is reported that irradiation is highly s...
Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology
Authors: Petar M. Seferovic, Piotr Ponikowski, Stefan D. Anker, Johann Bauersachs, Ovidiu Chioncel, John G.F. Cleland, Rudolf A. de Boer, Heinz Drexel, Tuvia Ben Gal, Loreena Hill, Tiny Jaarsma, Ewa A. Jankowska, Markus S. Anker, Mitja Lainscak, Basil S. Lewis, Theresa McDonagh, Marco Metra, Davor Milicic, Wilfried Mullens, Massimo F. Piepoli, Giuseppe Rosano, Frank Ruschitzka, Maurizio Volterrani, Adriaan A. Voors, Gerasimos Filippatos, Andrew J.S. Coats
Journal: European Journal of Heart Failure (2019)
Should pulmonary rehabilitation be a standard of care in lung cancer?
Authors: Michael C Steiner
Journal: Thorax (2019)

There are few therapeutic interventions as effective as pulmonary rehabilitation (PR) in the management of the chronic respiratory disease. The scientific evidence base demonstrating the clinical benefit of PR is incontestable, indeed the most recent iteration of the Cochrane systematic review summarising clinical trials of PR in chronic obstructive pulmonary disease (COPD) concluded that no further clinical trials testing effectiveness were needed.1 The gains in physical capacity and health-related quality of life conferred by PR in routine clinical practice are comparable to those seen in clinical trials2 and the available evidence suggests that completion of PR reduces subsequent healthcare costs through a reduction in the number of days spent in the hospital.3 This substantial body of evidence is derived largely from studies in people with COPD but, perhaps unsurprisingly, PR is also effective in other chronic respiratory diseases characterised by exercise limitation due to dyspnoea and muscle fatigue such as bronchiectasis, interstitial lung disease and pulmonary hypertension. This benefit, long understood by rehabilitation practitioners in the field, is increasingly now backed up by clinical trials of PR in these specific patient populations.4–6

In this issue of the journal, Edbrooke and colleagues further extend our understanding of the broader role of PR in respiratory disease by undertaking a clinical trial of a home-based rehabilitation intervention in patients receiving non-surgical therapy for lung cancer.7 The trial aimed to encourage participation in an 8-week programme of structured, progressive physical activity and exercise while volunteers were also attending medical centres for active cancer treatment (chemotherapy or radiotherapy, commenced no more than 4 weeks prior to enrolment). On the face of it, there is a strong rationale for such an intervention; patients presenting with inoperable lung cancer frequently have low-performance status, poor exercise capacity and are physically inactive.8 Rehabilitation …
DIAGNOSIS AND TREATMENT OF PATIENTS SUFFERING FROM AUTOIMMUNE DISEASES OF THE ESOPHAGUS, COMPLICATED BY BENIGH STRICTURE
Authors: M Korolev, L Fedotov, A Ogloblin, B Fedotov, D Luchinina
Journal: Endoscopy (2019)

Identification of the clinical features, diagnosis and treatment of 4 nosological units: mucous membrane pemphigoid (MMP), lichen planus (LP), eosinophilic esophagitis (EoE) and Crohn's disease (CD).
AI Identifies Implanted Cardiac Devices
Authors: Jennifer Abbasi
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PRIMARY EPITHELIOID ANGIOSARCOMA OF THE JEJUNUM: A RARE CAUSE OF UPPER GASTROINTESTINAL BLEED
Authors: F Nawaz, M Ahmed
Journal: Endoscopy (2019)

Gastrointestinal angiosarcoma is a rare and highly malignant soft tissue tumor constituting < 1% of all gastrointestinal malignancies and only 1% of all sarcomas. The objective of this case report, is to increase awareness of this rare tumour.
ERCP IN BILIARY PARASITOSIS – FROM DIAGNOSIS TO TREATMENT
Authors: J Fernandes, M Moreira, T Araújo, H Ribeiro, S Giestas, F Lucas, J Ramada, M Certo, J Canena, L Lopes
Journal: Endoscopy (2019)

We present the video of 4 patients with biliary parasitosis, diagnosed and treated by endoscopic retrograde cholangiopancreatography (ERCP), in a series of more than 3000 CPREs performed in a gastroenterology department (prevalence < 0.14%).
Apport de l'echoendoscopie dans la prise en charge chirurgicale des cancers de l'estomac et de la jonction oesogastrique
Authors: S Hoibian, F Caillol, A Autret, JP Ratone, C Pesenti, E Bories, J guiramand, P Ries, S Dermeche, M Giovannini
Journal: Endoscopy (2019)

L'echoendoscopie oeso-gastrique (EE) est recommandée par l'ESMO dans le bilan pré-thérapeutique des adénocarcinomes (ADK) de l'estomac pour évaluer le statut T et N afin de décider de la realisation d'un traitement pré-opératoire pour les tumeurs >T1 et/ou N+ (1). La localisation des ADK gastriques migre vers la jonction oesogastrique (JOG) (2). L'impact de l'EE sur la visualisation de lésions métastatiques, et l'évaluation post traitement pre-opératoire par EE reste controversé. Le but de cette étude rétrospective est l'évaluation de l'EE dans la prise en charge d'un ADK gastrique ou de la JOG.
Peroral Endoscopic Myotomy (POEM) dans le traitement de l'achalasie: est-ce le temps des recommandations de pratique clinique? Une enquête multicentrique européenne
Authors: JM Gonzalez, M Pioche, J Jacques, G Vanbiervliet, E Chabrun, J Branche, J Privat, T Wallenhorst, J Rivory, G Rahmi, V Lepilliez, A Charachon, S Leblanc, M Barthet, V Vitton
Journal: Endoscopy (2019)

Le POEM est devenu un traitement de référence sûr et très efficace de l'achalasie. Néanmoins, bien que certains aspects procéduraux semblent communément admis, d'autres points restent hétérogènes, notamment l'évaluation préopératoire, les indications du POEM, et le suivi et ses modalités. Etant donné son expansion, il y a nécessité de proposer des recommandations de pratique clinique. Nous proposons une enquête de pratiques auprès de centres experts POEM en première étape.